Abstract
Background: Bradykinin (BK) is a key mediator responsible for swelling episodes in hereditary angioedema due to C1INH deficiency/dysfunction (HAE-C1INH). Current BK measurement faces many challenges primarily related to very low levels and instability, and is not feasible for application in clinical settings. Objective: This study aimed to develop a novel method to overcome the issues in current protease inhibitor-based methods for measuring endogenous BK and its metabolites. Methods: The blood from HAE-C1INH and healthy volunteers were collected and subjected to cold activation for contact system. Cold-induced BK and its major metabolites were measured via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The protocol was established according to the US FDA bioanalytical validation guidelines as a CLIA laboratory-developed test. The BK measurement was optimized based on blood sample types, collection methods, time windows, and temperature/storage conditions. Results: EDTA whole blood samples without protease inhibitors incubated at 4 degree for 1 to 3 days produced over 100-fold differences in total BK levels between HAE-C1INH subjects and healthy volunteers (324.3 +/- 54.7 ng/mL, n=33; vs 2.3 +/- 0.3 ng/mL, n = 43; mean+/-S.E.M., p < 0.001). The sensitivity and specificity were 90.9% and 97.1% respectively. BK levels highly correlated with the plasma kallikrein activity in the same samples. Conclusions: Whole blood under cold activation demonstrated remarkable elevation of BK levels in HAE-C1INH subjects, while minimally affecting healthy individuals. The assay has validated accuracy, precision and stability. It may serve as a reliable and robust tool for HAE diagnosis and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Foundation for Rare Disease Research and Virant Diagnostics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted following the guidelines of a clinical study protocol approved by a central Virant Institutional Review Board (IRB protocol number: Virant-A0001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.